Integrilin (eptifibatide) is a protein pharmaceutical. Eptifibatide was first approved as Integrilin on 1998-05-18. It is used to treat coronary disease, myocardial infarction, and unstable angina in the USA. It has been approved in Europe to treat myocardial infarction and unstable angina.
|Indication||coronary disease, myocardial infarction, unstable angina|
|Drug Class||Peptides: platelet aggregation inhibitors (glycoprotein IIb/IIIa receptor antagonists)|